Antipruritic Market Outlook 2024 to 2034

The global antipruritic market size is projected to surpass a valuation of US$ 16.2 billion by 2034. Our healthcare analysts opine that antipruritic manufacturers can expect a CAGR of 4.2% through 2034, with a current valuation of US$ 10.9 billion in 2024.

Attributes Market Insights
Market Value 2023 US$ 10.5 billion
Market Value 2024 US$ 10.9 billion
Market Value 2034 US$ 16.2 billion
CAGR 2024 to 2034 4.2%
Market Share of Top 5 Countries 60.8%

Pruritus is a complex process that frequently happens with skin conditions, including atopic dermatitis and urticaria, and may harm quality of life. Additionally, it might be a sign of an underlying medical condition, such as hyperthyroidism or cholestasis, or it might just be the result of dry skin, especially during the chilly winter months.

Therapy focuses on treating the itching first, then addressing the underlying cause. Herbal therapies, prescription and over-the-counter (OTC) drugs, hydrotherapy, phototherapy, and UV therapy are all possible forms of treatment.

Key Market Highlights:

  • To improve efficacy and patient compliance, ongoing research and development are anticipated to drive advances in antipruritic formulations such as topical creams, ointments, and innovative delivery modalities.
  • A significant trend is the development of biological treatments for skin conditions that cause pruritus. Biologics have the potential to change the therapeutic landscape by providing focused and effective therapies for specific illnesses.
  • With the growing frequency of skin illnesses such as eczema, psoriasis, and dermatitis, there is an increased emphasis on creating antipruritic remedies suited to these specific dermatological problems.
  • Incorporating new technologies, such as AI-driven diagnostics or smart devices for monitoring and controlling pruritus, have emerged as antipruritic market trends.
  • The incorporation of antipruritic management into telehealth systems and electronic health records represents a new trend, particularly given the increased popularity of remote healthcare services.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Historical Performance of Antipruritic Market (2019 to 2023) Vs. Forecast Outlook (2024 to 2034)

Attributes Details
Antipruritic Market Size (2019) US$ 9.1 billion
Antipruritic Market Size (2023) US$ 10.5 billion
Antipruritic Market CAGR (2019 to 2023) 4.1%

The market observed a growth of 4.1% during 2019 and 2023. The global market for antipruritic held nearly 64.6% of the overall US$ 15.7 billion skin treatment market shares in 2023.

The most frequent dermatologic symptom reported by patients is pruritus. It is associated with a variety of skin conditions, the majority of which are characterized by primary lesions such as vesicles, plaques, and papules.

The underlying causes of pruritus are still unknown, making it difficult for healthcare practitioners to control itching in individuals with severe pruritus adequately. There are typically discrepancies between causative and symptomatic approaches to pruritus therapy. A common strategy for navigating the broad terrain of pruritus therapy is to categorize these alternatives according to their underlying causes.

Causative therapy aims to identify and treat the underlying illness causing the itching. Symptomatic treatment hides the itch through treatments such as cooling, heating, or counter-irritation (e.g., scratching). To provide relief sooner, symptomatic treatment and addressing the underlying disease process may be used. The popular therapeutic options are classified as symptomatic therapy and management.

Disruptive technical advancements, increasing healthcare investments, and health system optimization are driving the swift development of the medical and drug industries. Modern medical institutions, ambulatory care centers, and clinics throughout the world are deliberately adopting cutting-edge technological technologies and equipment into their operations to improve efficiency and competitiveness.

The global market's revenue growth is fuelled by factors such as rising chronic illness incidence, rapid improvements in the healthcare and medical sectors, widespread use of new instruments and techniques, and increased funding from various public and private sectors.

Furthermore, rising emphasis on drug discovery, rising need for precision medicine, widespread deployment of home care services and point-of-care diagnostics, and increased investments in R&D activities are likely to boost global market revenue and profit during the projected timeframe.

These factors are projected to impact the growth of the industry worldwide positively. With a CAGR of 4.2%, the industry is predicted to develop significantly during the following decade.

Comparative View of Markets Adjacent to Antipruritic

Future Market Insights (FMI) has compared two other markets, the dermal fillers and the dermatology laser market. As per the analysis, the rising prevalence of dermatological disorders such as psoriasis and vitiligo influences demand across the mentioned markets. The expanding geriatric population and their age-related skin disorders contribute to this demand. The growth of telemedicine and online healthcare platforms is making healthcare more accessible, driving the growth of the mentioned markets. The increasing expenditure on healthcare and skincare is likely to bolster growth across the mentioned markets in the coming years.

Antipruritic Market:

Attributes Antipruritic Market
CAGR (2024 to 2034) 4.2%
Growth Factors
  • Expanding geriatric population and associated skin diseases.
  • Growing demand for topical treatments.
Future Opportunities Advances in formulation technologies.
Market Trends Growth of telemedicine and online healthcare platforms.

Dermal Filler Market:

Attributes Dermal Filler Market
CAGR (2024 to 2034) 7.5%
Growth Factors
  • The rising shift toward minimally invasive cosmetic procedures.
  • Increasing investment in research and development.
Future Opportunities New product launches and regional market expansions.
Market Trends Increasing demand for minimally invasive facial treatments.

Dermatology Laser Market:

Attributes Dermatology Laser Market
CAGR (2024 to 2034) 7.0%
Growth Factors
  • Rising skin cancer and other chronic diseases.
  • Growing awareness for sophisticated cosmetic procedures.
Future Opportunities Development of novel technologies for skin treatment.
Market Trends Rising prevalence of skin illnesses.
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Key Opportunities in the Antipruritic Market

Chronic pruritus, a growing health problem, significantly impacts quality of life. Ongoing research has revealed new pathways and itch receptors, which has improved our understanding of these aspects. Expectations are strong that these latest insights are going to encourage the development of ground-breaking treatments for this frequently ignored and inconvenient ailment.

The administration of medications that reduce neural sensitization to pain, such as gabapentin, pregabalin, SSRIs, and norepinephrine antidepressants, either singly or in combination, is now required for the therapeutic management of chronic pruritus.

In the future, adopting a variety of topical and systemic medicines that focus on the different receptors and neurological pathways mediating distinct forms of itch would improve the quality of life for millions of pruritic patients.

Factors that Present a Restrictive Outlook for the Market

Because of the condition's complex etiology and various contributing factors, treating chronic pruritus (CP) remains challenging. Despite the well-known antipruritic properties of traditional pharmacotherapy, such as topical therapy, light therapy, and systemic therapy, these strategies typically fail to provide significant relief for affected individuals.

Despite the wide range of therapy options, chronic pruritus is still challenging to treat. Several antipruritic treatments are still used off-label as of right now. There are currently just a few effective topical treatments for itching, and existing itch management techniques do not cover most unmet needs.

Furthermore, few published works employ general health metrics to evaluate CP, and there are very few economic statistics on the cost of chronic pruritus. According to the American Academy of Dermatology's (AAD) National Burden of Skin Disease report, pruritus-related disorders in the United States incur a yearly treatment expense of US$ 294 million and an opportunity cost of US$ 107 million (2017).

According to Luk et al. (2020), people with CP have an annual financial burden of US$ 1,067 because of both direct and secondary medical costs. The impact of stress, anxiety, depression, and functional incapacity on the patient and their loved ones as a result of the condition are examples of what are known as intangible costs that are not taken into account by current techniques of cost assessment.

During the forecast period, the market is expected to experience barriers in its growth trajectory due to a significant financial burden, limited evidence-based data, and parameters associated with existing treatment alternatives.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Country-wise Insights

Countries CAGR (2024 to 2034)
United States 37.4%
China 8.9%
Germany 4.70%
United Kingdom 5.10%
Japan 3.20%

The United States Emerges as the Leading Market for Antipruritic

The United States dominated the antipruritic market with 37.4% of market shares in 2023. The antipruritic market size in the United States is estimated to rise at a 4.30% CAGR through 2034. The country has a vast healthcare system includes comprehensive patient care and reimbursement provisions. Moreover, with greater patient awareness regarding various treatment modalities and options for pruritus treatments, the country holds a leading stance within the global market.

China is Considered a Lucrative Market for Antipruritic

China captured a value share of 8.9% in the global market in 2023. The demand for antipruritic treatments is projected to surge at a 6.90% CAGR through 2034. It has been observed in several population-based studies that in Chinese patients, the frequency and severity of pruritus vary with skin conditions, skin type, age, and gender.

According to GBD 2019, young and middle-aged demographics have a higher illness burden from acne. Nearly 9.4% of the world’s population suffers from acne, making it the 8th most widespread condition globally. The market for antipruritics is driven by the increased prevalence of skin diseases in China, providing key producers with opportunities to expand within the country.

Sales Outlook for Germany in the Global Market

Germany held around 5.7% of the antipruritic market in 2023. The market for antipruritic in Germany is predicted to thrive at a 4.70% CAGR through 2034. In Germany, a surprisingly high number of pruritus sufferers, particularly those with specific localizations on the body, have unmet medical needs. This factor promotes opportunities for established manufacturers within the country to promote and develop novel therapeutics, addressing these unmet needs, hence propelling growth throughout the forecast period.

Rising Telemedicine Adoption Surges Market Growth in the United Kingdom

The United Kingdom held nearly 3.50% of the market shares in 2023. The demand for antipruritic in the United Kingdom is estimated to rise at a 5.10% CAGR through 2034. The introduction of telemedicine services in the United Kingdom has unlocked the door to online consultations and prescriptions for antipruritic drugs, increasing access to healthcare services. Government subsidies or incentives for research and development could appeal to pharmaceutical businesses to invest in producing new and improved antipruritic remedies.

Technological Developments in Dermatology Spur Expansion in Japan

Japan held nearly 5.20% of the market shares in 2023. The antipruritic market size in Japan is projected to surge at a 3.20% CAGR through 2034. Skincare and appearance are highly valued in Japanese society. A robust cultural preference for preserving good skin increases demand for antipruritic treatments, particularly those with aesthetic advantages. Japan is famous for its technological advances. Integration of cutting-edge technology, such as smart skincare devices or AI-driven diagnostic tools for dermatological diseases, could represent a differentiating element in market growth.

Category-wise Insights

Immunosuppressants Experience High Adoption on a Global Scale

Segment Immunosuppressants (Drug Type)
Value Share (2024) 31.3%

Immunosuppressants held a share of around 31.3% in the global market in 2023. This is due to the effectiveness of oral immunosuppressants such as cyclosporine, mycophenolate mofetil, and azathioprine in treating itching caused by inflammatory disorders like atopic dermatitis. Furthermore, systemic corticosteroids can also be administered to reduce inflammation in extreme situations of chronic pruritus.

The most effective way to reduce itching in atopic dermatitis is to manage the inflammation with topical or systemic immunosuppressive medications effectively.

Psoriasis Disease is a Large Concern within the Global Market

Segment Psoriasis (Disease Type)
Value Share (2024) 33.2%

Psoriasis held around 33.2% of the global market in 2023. Psoriasis is a prevalent, chronic illness that has no cure. According to the 2019 report on the worldwide disease burden, there have been 4,622,594 reported cases of psoriasis globally in that year. The age range of 60 to 69 years has the maximum prevalence of psoriasis overall, with a roughly equal frequency between men and women.

The burden is substantially heavier in North American and European countries with high incomes and high SDI indices. To help reduce the disease burden of psoriasis globally, this factor fuels the interest of manufacturers in the market in the development of novel therapies.

Oral Route of Administration is Highly Preferred in the Antipruritic Market

Segment Oral (Route of Administration)
Value Share (2024) 39.8%

The oral route of administration held a share of around 39.8% in the global market in 2023. This is due to the usage of oral antihistamines for the symptomatic alleviation of pruritus. Oral antihistamines of the first or second generations, such as cetirizine and loratadine, are widely recommended. First-generation oral antihistamines include diphenhydramine and hydroxyzine.

Moreover, due to the ease of administration of oral medication dosages, the oral route of administration gains a more significant share within the global market.

Hospital Pharmacies Distribution Channel Reap Great Benefits

Segment Hospital Pharmacies (Distribution Channel)
Value Share (2024) 30.4%

Hospital pharmacies held around 30.4% of the global market in 2023. Several institutional pharmacies provide commonly prescribed medications for pruritus at subsidized rates, thus propelling sales of antipruritics within these settings. Moreover, with the ease of dispensing, presence of branded and generic drug options, as well as greater accessibility to patients, this segment holds a dominant share within the global market.

Competitive Landscape

Key players are enhancing their research and development activities to launch novel products. The expansion of their product range and efforts to improve their pipelined products are two other strategic acquisitions and partnerships with key businesses.

Recent Developments

  • In May 2023, Biofrontera announced that the care foam Belixos ACTIVE CARE was added to the active cosmetic series Belixos. Topical dermatitis and psoriasis patients' go-to treatment for basic or extensive skin issues can benefit from using Belixos ACTIVE CARE, a skin-soothing care foam for irritated and itchy skin.
  • In October 2022, Sonoma Pharmaceuticals, Inc., a leader in the global healthcare industry that develops and produces stabilized hypochlorous acid (HOCl) products based on patented Microcyn technology for a variety of applications, including wound, eye, oral, and nasal care, as well as dermatological conditions, announced the launch of Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel and Rejuvacyn Advanced Skin Repair Cooling Mist for consumers in the United States for over-the-counter use.
  • The new atopic dermatitis therapy Moizerto Ointment (generic name: difamilast), available in 1 percent and 0.3 percent formulations, was introduced in Japan on June 1, 2022, according to a statement from Otsuka Pharmaceutical Co., Ltd. (Otsuka).
  • The United States FDA authorized Pfizer's CIBINQO (abrocitinib) in January 2022 for use in individuals with moderate-to-severe atopic dermatitis.
  • In May 2020, Sanofi received United States FDA approval for its Dupixent (dupilumab), the first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis.

Report Scope as per Antipruritics Industry Analysis

Attribute Details
Forecast Period 2024 to 2034
Historical Data Available for 2019 to 2023
Market Analysis US$ billion for Value
Key Regions Covered North America, Latin America, Europe, South Asia, East Asia, Oceania, the Middle East and Africa (MEA)
Key Countries Covered United States, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, Spain, United Kingdom, Russia, BENELUX, China, Japan, South Korea, India, Indonesia, Thailand, Malaysia, Australia, New Zealand, GCC Countries, Turkey, North Africa, South Africa
Key Companies Covered
  • AbbVie Inc.
  • Allergan, Merck & Co., Inc.
  • Amgen Inc.
  • Pfizer Inc.
  • Cara Therapeutics
  • Enteris BioPharma
  • NeRRe Therapeutics
  • Menlo Therapeutics
  • XBiotech Inc.
  • Ipsen Pharma
  • Eledon Pharmaceuticals, Inc.
  • Amorepacific
  • RDD Pharma, Ltd
  • Novartis AG
  • AstraZeneca
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Cipla Ltd.
Key Market Segments Covered Drug, Disease, Route of Administration, Distribution Channel, and Region
Pricing Available upon Request

Key Segments Covered in Antipruritics Industry Research

By Drug:

  • Corticosteroids
  • Antihistamines
  • Local Anaesthetics
  • Immunosuppressants
  • Others

By Disease:

  • Atopic Dermatitis
  • Allergic Contact Dermatitis
  • Urticaria
  • Psoriasis

By Route of Administration:

  • Oral
  • Parenteral
  • Topical

By Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Online Stores

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East & Africa (MEA)

Frequently Asked Questions

How Much is the Antipruritic Market Currently Worth?

The global antipruritic market is worth US$ 10.9 billion in 2024.

What is the Sales Forecast for Antipruritic through 2034?

The market is expected to reach US$ 16.2 billion by the end of 2034 at a CAGR of 4.2%.

What are the Trends Driving the Global Antipruritic Market?

The growing geriatric population, rising burden of skin diseases, and rising R&D on novel biopharmaceuticals.

Which Region is Developing at a Higher CAGR in the Global Antipruritic Market?

The antipruritic market in East Asia and Latin America is expanding at 4.7% CAGR.

What is the Projection for the Antipruritic Market in Europe?

Europe is projected to develop with a CAGR of 4.2% during the forecast period.

Which are the Top Five Countries Driving Demand for Antipruritic?

The United States, the United Kingdom, China, Japan, and Germany are the top five countries in the market.

Who are the Key Manufacturers in the Antipruritic Market?

AbbVie Inc., Allergan, Merck & Co., Inc., and Pfizer Inc. are some key players in the antipruritics industry.

What were the last five years' CAGR for the Antipruritic Market?

From 2019 to 2023, the antipruritics market expanded at a 4.1% CAGR.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Key Innovation / Development Trends

4. Key Success Factors

    4.1. Promotional Strategies, By Key Manufacturers

    4.2. Key Regulations

    4.3. Reimbursement Scenario

    4.4. PESTEL Analysis

    4.5. Porter’s Analysis

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Global Healthcare Expenditure Outlook

        5.1.3. Global Skin Treatment Market Outlook

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Prevalence of Dermal Illnesses

        5.2.2. Growing Funding for Research and Development

        5.2.3. Vast Product Pipeline

        5.2.4. Availability of Alternate Drugs

        5.2.5. New Product Launch Activities

        5.2.6. Regulatory Approvals

        5.2.7. Product Accessibility

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033

    6.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022

    6.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033

        6.2.1. Y-o-Y Growth Trend Analysis

        6.2.2. Absolute $ Opportunity Analysis

7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Million) Analysis By Drug, 2017 to 2022

    7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug, 2023 to 2033

        7.3.1. Corticosteroids

        7.3.2. Antihistamines

        7.3.3. Local Anesthetics

        7.3.4. Immunosuppressant’s

        7.3.5. Others

    7.4. Market Attractiveness Analysis By Drug

8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Disease

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Million) Analysis By Disease , 2017 to 2022

    8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Disease, 2023 to 2033

        8.3.1. Atopic Dermatitis

        8.3.2. Allergic Contact Dermatitis

        8.3.3. Urticaria

        8.3.4. Psoriasis

    8.4. Market Attractiveness Analysis By Disease

9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route of Administration

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Million) Analysis By Route of Administration, 2017 to 2022

    9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        9.3.1. Oral

        9.3.2. Parenteral

        9.3.3. Topical

    9.4. Market Attractiveness Analysis By Route of Administration

10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2017 to 2022

    10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        10.3.1. Hospital Pharmacies

        10.3.2. Drug Stores

        10.3.3. Retail Pharmacies

        10.3.4. Online Stores

    10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Million) Analysis By Region, 2017 to 2022

    11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        11.3.1. North America

        11.3.2. Latin America

        11.3.3. Europe

        11.3.4. East Asia

        11.3.5. South Asia

        11.3.6. Oceania

        11.3.7. Middle East and Africa

    11.4. Market Attractiveness Analysis By Region

12. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    12.1. Introduction

    12.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    12.3. Current and Future Market Size (US$ Million) Analysis & Forecast By Market Taxonomy, 2023 to 2033

        12.3.1. By Country

            12.3.1.1. USA

            12.3.1.2. Canada

        12.3.2. By Drug

        12.3.3. By Disease

        12.3.4. By Route of Administration

        12.3.5. By Distribution Channel

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Drug

        12.4.3. By Disease

        12.4.4. By Route of Administration

        12.4.5. By Distribution Channel

    12.5. Market Trends

    12.6. Key Market Participants - Intensity Mapping

    12.7. Drivers and Restraints - Impact Analysis

    12.8. Country Level Analysis & Forecast

        12.8.1. USA Market Analysis

            12.8.1.1. Introduction

            12.8.1.2. Market Analysis and Forecast By Market Taxonomy

                12.8.1.2.1. By Drug

                12.8.1.2.2. By Disease

                12.8.1.2.3. By Route of Administration

                12.8.1.2.4. By Distribution Channel

        12.8.2. Canada Market Analysis

            12.8.2.1. Introduction

            12.8.2.2. Market Analysis and Forecast By Market Taxonomy

                12.8.2.2.1. By Drug

                12.8.2.2.2. By Disease

                12.8.2.2.3. By Route of Administration

                12.8.2.2.4. By Distribution Channel

13. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    13.1. Introduction

    13.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    13.3. Current and Future Market Size (US$ Million) Analysis & Forecast By Market Taxonomy, 2023 to 2033

        13.3.1. By Country

            13.3.1.1. Mexico

            13.3.1.2. Brazil

            13.3.1.3. Argentina

            13.3.1.4. Rest of Latin America

                13.3.1.4.1. By Drug

                13.3.1.4.2. By Disease

                13.3.1.4.3. By Route of Administration

                13.3.1.4.4. By Distribution Channel

    13.4. Market Attractiveness Analysis

                13.4.1.1.1. By Country

                13.4.1.1.2. By Drug

                13.4.1.1.3. By Disease

                13.4.1.1.4. By Route of Administration

                13.4.1.1.5. By Distribution Channel

    13.5. Market Trends

    13.6. Key Market Participants - Intensity Mapping

    13.7. Drivers and Restraints - Impact Analysis

    13.8. Country Level Analysis & Forecast

        13.8.1. Mexico Market Analysis

            13.8.1.1. Introduction

            13.8.1.2. Market Analysis and Forecast By Market Taxonomy

                13.8.1.2.1. By Drug

                13.8.1.2.2. By Disease

                13.8.1.2.3. By Route of Administration

                13.8.1.2.4. By Distribution Channel

        13.8.2. Brazil Market Analysis

            13.8.2.1. Introduction

            13.8.2.2. Market Analysis and Forecast By Market Taxonomy

                13.8.2.2.1. By Drug

                13.8.2.2.2. By Disease

                13.8.2.2.3. By Route of Administration

                13.8.2.2.4. By Distribution Channel

        13.8.3. Argentina Market Analysis

            13.8.3.1. Introduction

            13.8.3.2. Market Analysis and Forecast By Market Taxonomy

                13.8.3.2.1. By Drug

                13.8.3.2.2. By Disease

                13.8.3.2.3. By Route of Administration

                13.8.3.2.4. By Distribution Channel

14. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    14.1. Introduction

    14.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    14.3. Current and Future Market Size (US$ Million) Analysis & Forecast By Market Taxonomy, 2023 to 2033

        14.3.1. By Country

            14.3.1.1. Germany

            14.3.1.2. Italy

            14.3.1.3. France

            14.3.1.4. UK

            14.3.1.5. Spain

            14.3.1.6. BENELUX

            14.3.1.7. Russia

            14.3.1.8. Rest of Europe

        14.3.2. By Drug

        14.3.3. By Disease

        14.3.4. By Route of Administration

        14.3.5. By Distribution Channel

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Drug

        14.4.3. By Disease

        14.4.4. By Route of Administration

        14.4.5. By Distribution Channel

    14.5. Market Trends

    14.6. Key Market Participants - Intensity Mapping

    14.7. Drivers and Restraints - Impact Analysis

    14.8. Country Level Analysis & Forecast

        14.8.1. Germany Market Analysis

            14.8.1.1. Introduction

            14.8.1.2. Market Analysis and Forecast By Market Taxonomy

                14.8.1.2.1. By Drug

                14.8.1.2.2. By Disease

                14.8.1.2.3. By Route of Administration

                14.8.1.2.4. By Distribution Channel

        14.8.2. Italy Market Analysis

            14.8.2.1. Introduction

            14.8.2.2. Market Analysis and Forecast By Market Taxonomy

                14.8.2.2.1. By Drug

                14.8.2.2.2. By Disease

                14.8.2.2.3. By Route of Administration

                14.8.2.2.4. By Distribution Channel

        14.8.3. France Market Analysis

            14.8.3.1. Introduction

            14.8.3.2. Market Analysis and Forecast By Market Taxonomy

                14.8.3.2.1. By Drug

                14.8.3.2.2. By Disease

                14.8.3.2.3. By Route of Administration

                14.8.3.2.4. By Distribution Channel

        14.8.4. UK Market Analysis

            14.8.4.1. Introduction

            14.8.4.2. Market Analysis and Forecast By Market Taxonomy

                14.8.4.2.1. By Drug

                14.8.4.2.2. By Disease

                14.8.4.2.3. By Route of Administration

                14.8.4.2.4. By Distribution Channel

        14.8.5. Spain Market Analysis

            14.8.5.1. Introduction

            14.8.5.2. Market Analysis and Forecast By Market Taxonomy

                14.8.5.2.1. By Drug

                14.8.5.2.2. By Disease

                14.8.5.2.3. By Route of Administration

                14.8.5.2.4. By Distribution Channel

        14.8.6. BENELUX Market Analysis

            14.8.6.1. Introduction

            14.8.6.2. Market Analysis and Forecast By Market Taxonomy

                14.8.6.2.1. By Drug

                14.8.6.2.2. By Disease

                14.8.6.2.3. By Route of Administration

                14.8.6.2.4. By Distribution Channel

        14.8.7. Russia Market Analysis

            14.8.7.1. Introduction

            14.8.7.2. Market Analysis and Forecast By Market Taxonomy

                14.8.7.2.1. By Drug

                14.8.7.2.2. By Disease

                14.8.7.2.3. By Route of Administration

                14.8.7.2.4. By Distribution Channel

15. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    15.1. Introduction

    15.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    15.3. Current and Future Market Size (US$ Million) Analysis & Forecast By Market Taxonomy, 2023 to 2033

        15.3.1. By Country

            15.3.1.1. China

            15.3.1.2. Japan

            15.3.1.3. South Korea

        15.3.2. By Drug

        15.3.3. By Disease

        15.3.4. By Route of Administration

        15.3.5. By Distribution Channel

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Drug

        15.4.3. By Disease

        15.4.4. By Route of Administration

        15.4.5. By Distribution Channel

    15.5. Market Trends

    15.6. Key Market Participants - Intensity Mapping

    15.7. Drivers and Restraints - Impact Analysis

    15.8. Country Level Analysis & Forecast

        15.8.1. China Market Analysis

            15.8.1.1. Introduction

            15.8.1.2. Market Analysis and Forecast By Market Taxonomy

                15.8.1.2.1. By Drug

                15.8.1.2.2. By Disease

                15.8.1.2.3. By Route of Administration

                15.8.1.2.4. By Distribution Channel

        15.8.2. Japan Market Analysis

            15.8.2.1. Introduction

            15.8.2.2. Market Analysis and Forecast By Market Taxonomy

                15.8.2.2.1. By Drug

                15.8.2.2.2. By Disease

                15.8.2.2.3. By Route of Administration

                15.8.2.2.4. By Distribution Channel

        15.8.3. South Korea Market Analysis

            15.8.3.1. Introduction

            15.8.3.2. Market Analysis and Forecast By Market Taxonomy

                15.8.3.2.1. By Drug

                15.8.3.2.2. By Disease

                15.8.3.2.3. By Route of Administration

                15.8.3.2.4. By Distribution Channel

16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    16.1. Introduction

    16.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    16.3. Current and Future Market Size (US$ Million) Analysis & Forecast By Market Taxonomy, 2023 to 2033

        16.3.1. By Country

            16.3.1.1. India

            16.3.1.2. Indonesia

            16.3.1.3. Malaysia

            16.3.1.4. Thailand

            16.3.1.5. Rest of South Asia

        16.3.2. By Drug

        16.3.3. By Disease

        16.3.4. By Route of Administration

        16.3.5. By Distribution Channel

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Drug

        16.4.3. By Disease

        16.4.4. By Route of Administration

        16.4.5. By Distribution Channel

    16.5. Market Trends

    16.6. Key Market Participants - Intensity Mapping

    16.7. Drivers and Restraints - Impact Analysis

    16.8. Country Level Analysis & Forecast

        16.8.1. India Market Analysis

            16.8.1.1. Introduction

            16.8.1.2. Market Analysis and Forecast By Market Taxonomy

                16.8.1.2.1. By Drug

                16.8.1.2.2. By Disease

                16.8.1.2.3. By Route of Administration

                16.8.1.2.4. By Distribution Channel

        16.8.2. Indonesia Market Analysis

            16.8.2.1. Introduction

            16.8.2.2. Market Analysis and Forecast By Market Taxonomy

                16.8.2.2.1. By Drug

                16.8.2.2.2. By Disease

                16.8.2.2.3. By Route of Administration

                16.8.2.2.4. By Distribution Channel

        16.8.3. Malaysia Market Analysis

            16.8.3.1. Introduction

            16.8.3.2. Market Analysis and Forecast By Market Taxonomy

                16.8.3.2.1. By Drug

                16.8.3.2.2. By Disease

                16.8.3.2.3. By Route of Administration

                16.8.3.2.4. By Distribution Channel

        16.8.4. Thailand Market Analysis

            16.8.4.1. Introduction

            16.8.4.2. Market Analysis and Forecast By Market Taxonomy

                16.8.4.2.1. By Drug

                16.8.4.2.2. By Disease

                16.8.4.2.3. By Route of Administration

                16.8.4.2.4. By Distribution Channel

17. Oceania Market 2017 to 2022 and Forecast 2023 to 2033

    17.1. Introduction

    17.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    17.3. Current and Future Market Size (US$ Million) Analysis & Forecast By Market Taxonomy, 2023 to 2033

        17.3.1. By Country

            17.3.1.1. Australia

            17.3.1.2. New Zealand

        17.3.2. By Drug

        17.3.3. By Disease

        17.3.4. By Route of Administration

        17.3.5. By Distribution Channel

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Drug

        17.4.3. By Disease

        17.4.4. By Route of Administration

        17.4.5. By Distribution Channel

    17.5. Key Market Participants - Intensity Mapping

    17.6. Drivers and Restraints - Impact Analysis

    17.7. Country Level Analysis & Forecast

        17.7.1. Australia Market Analysis

            17.7.1.1. Introduction

            17.7.1.2. Market Analysis and Forecast By Market Taxonomy

                17.7.1.2.1. By Drug

                17.7.1.2.2. By Disease

                17.7.1.2.3. By Route of Administration

                17.7.1.2.4. By Distribution Channel

        17.7.2. New Zealand Market Analysis

            17.7.2.1. Introduction

            17.7.2.2. Market Analysis and Forecast By Market Taxonomy

                17.7.2.2.1. By Drug

                17.7.2.2.2. By Disease

                17.7.2.2.3. By Route of Administration

                17.7.2.2.4. By Distribution Channel

18. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    18.1. Introduction

    18.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    18.3. Current and Future Market Size (US$ Million) Analysis & Forecast By Market Taxonomy, 2023 to 2033

        18.3.1. By Country

            18.3.1.1. GCC Countries

            18.3.1.2. Türkiye

            18.3.1.3. South Africa

            18.3.1.4. North Africa

            18.3.1.5. Rest of Middle East and Africa

        18.3.2. By Drug

        18.3.3. By Disease

        18.3.4. By Route of Administration

        18.3.5. By Distribution Channel

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Drug

        18.4.3. By Disease

        18.4.4. By Route of Administration

        18.4.5. By Distribution Channel

    18.5. Market Trends

    18.6. Key Market Participants - Intensity Mapping

    18.7. Drivers and Restraints - Impact Analysis

    18.8. Country Level Analysis & Forecast

        18.8.1. GCC Countries Market Analysis

            18.8.1.1. Introduction

            18.8.1.2. Market Analysis and Forecast By Market Taxonomy

                18.8.1.2.1. By Drug

                18.8.1.2.2. By Disease

                18.8.1.2.3. By Route of Administration

                18.8.1.2.4. By Distribution Channel

        18.8.2. Türkiye Market Analysis

            18.8.2.1. Introduction

            18.8.2.2. Market Analysis and Forecast By Market Taxonomy

                18.8.2.2.1. By Drug

                18.8.2.2.2. By Disease

                18.8.2.2.3. By Route of Administration

                18.8.2.2.4. By Distribution Channel

        18.8.3. South Africa Market Analysis

            18.8.3.1. Introduction

            18.8.3.2. Market Analysis and Forecast By Market Taxonomy

                18.8.3.2.1. By Drug

                18.8.3.2.2. By Disease

                18.8.3.2.3. By Route of Administration

                18.8.3.2.4. By Distribution Channel

        18.8.4. North Africa Market Analysis

            18.8.4.1. Introduction

            18.8.4.2. Market Analysis and Forecast By Market Taxonomy

                18.8.4.2.1. By Drug

                18.8.4.2.2. By Disease

                18.8.4.2.3. By Route of Administration

                18.8.4.2.4. By Distribution Channel

19. Market Structure Analysis

    19.1. Market Analysis By Tier of Companies

    19.2. Market Concentration

    19.3. Market Share Analysis of Top Players

    19.4. Market Presence Analysis

20. Competition Analysis

    20.1. Competition Dashboard

    20.2. Competition Benchmarking

    20.3. Competition Deep Dive

        20.3.1. AbbVie Inc.

            20.3.1.1. Overview

            20.3.1.2. Product Portfolio

            20.3.1.3. Sales Footprint

            20.3.1.4. Key Financials

            20.3.1.5. SWOT Analysis

            20.3.1.6. Strategic Overview

        20.3.2. Allergan, Merck & Co., Inc.

        20.3.3. Amgen Inc.

        20.3.4. Pfizer Inc.

        20.3.5. Cara Therapeutics

        20.3.6. Enteris BioPharma

        20.3.7. NeRRe Therapeutics

        20.3.8. Menlo Therapeutics

        20.3.9. XBiotech Inc.

        20.3.10. Ipsen Pharma

        20.3.11. Eledon Pharmaceuticals, Inc.

        20.3.12. Amorepacific

        20.3.13. RDD Pharma, Ltd

        20.3.14. Novartis AG

        20.3.15. Astrazeneca

        20.3.16. Sanofi

        20.3.17. Sun Pharmaceutical Industries Ltd.

        20.3.18. Teva Pharmaceutical Industries Ltd.

        20.3.19. Takeda Pharmaceutical Company Limited

        20.3.20. Cipla Ltd.

21. Assumptions and Acronyms Used

22. Research Methodology

Recommendations

Healthcare

Dermal Filler Market

February 2021

REP-GB-5699

January 2024

250 pages

Healthcare

Dermatology Lasers Market

October 2020

REP-GB-12662

March 2023

306 pages

Explore Healthcare Insights

View Reports